New understanding of lung cancer cells’ ‘memories’ suggests novel treatment approach

No­vo Nordisk’s di­a­betes treat­ment Ozem­pic could be the drug in­dus­try’s sec­ond-high­est sell­er in 2024, ac­cord­ing to Eval­u­ate’s lat­est fore­cast, as an­a­lysts and physi­cians sig­nal the

Bio­gen’s lead­ers de­fend­ed their Ei­sai-part­nered Leqem­bi dur­ing a first-quar­ter earn­ings up­date on Wednes­day, say­ing the Alzheimer’s treat­ment is on a path to greater up­take as